Media stories about Immunomedics (NASDAQ:IMMU) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immunomedics earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.3329429281625 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
IMMU has been the topic of a number of recent analyst reports. Jefferies Group raised their price target on shares of Immunomedics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, October 9th. Zacks Investment Research raised shares of Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Wednesday, October 4th. BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Finally, ValuEngine lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a report on Monday, December 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Immunomedics currently has an average rating of “Buy” and a consensus price target of $15.33.
Shares of Immunomedics (NASDAQ:IMMU) opened at $15.47 on Wednesday. The stock has a market cap of $2,350.00, a price-to-earnings ratio of -6.91 and a beta of 1.48. Immunomedics has a twelve month low of $3.83 and a twelve month high of $17.24. The company has a debt-to-equity ratio of -0.29, a current ratio of 0.74 and a quick ratio of 0.74.
Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.06). equities analysts expect that Immunomedics will post -1.16 earnings per share for the current year.
In other news, Director Brian A. Markison sold 8,390 shares of the firm’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $11.89, for a total value of $99,757.10. Following the completion of the sale, the director now directly owns 99,178 shares of the company’s stock, valued at approximately $1,179,226.42. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Behzad Aghazadeh bought 1,325,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The stock was bought at an average cost of $10.47 per share, with a total value of $13,872,750.00. The disclosure for this purchase can be found here. 6.60% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Immunomedics (IMMU) Receives Daily News Impact Rating of 0.11” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/17/immunomedics-immu-receives-daily-news-impact-rating-of-0-11.html.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.